NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Psychiatric Disorders – Pipeline Review, H1 2013
Psychiatric Disorders – Pipeline Review, H1 2013
Summary
Global Markets Direct's, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Psychiatric Disorders.
- A review of the Psychiatric Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psychiatric Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Psychiatric Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psychiatric Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 13
Introduction 15
Global Markets Direct Report Coverage 15
Psychiatric Disorders Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Psychiatric Disorders 17
Psychiatric Disorders Therapeutics under Development by Companies 19
Psychiatric Disorders Therapeutics under Investigation by Universities/Institutes 34
Late Stage Products 40
Comparative Analysis 40
Mid Clinical Stage Products 41
Comparative Analysis 41
Early Clinical Stage Products 42
Comparative Analysis 42
Discovery and Pre-Clinical Stage Products 43
Comparative Analysis 43
Psychiatric Disorders Therapeutics – Products under Development by Companies 44
Psychiatric Disorders Therapeutics – Products under Investigation by Universities/Institutes 69
Companies Involved in Psychiatric Disorders Therapeutics Development 76
Bristol-Myers Squibb Company 76
DURECT Corporation 77
Johnson & Johnson 78
F. Hoffmann-La Roche Ltd. 79
Aradigm Corporation 80
Amgen Inc. 81
Sanofi-Aventis 82
AstraZeneca PLC 83
Eli Lilly and Company 84
BioDelivery Sciences International, Inc. 85
Athersys, Inc. 86
GlaxoSmithKline plc 87
Tekmira Pharmaceuticals Corp. 88
Alkermes, Inc. 89
Merck & Co., Inc. 90
Dainippon Sumitomo Pharma Co., Ltd. 91
Taisho Pharmaceutical Co., Ltd. 92
Euroscreen S.A. 93
Otsuka Pharmaceutical Co., Ltd. 94
Takeda Pharmaceutical Company Limited 95
Egalet a/s 96
CardioVascular BioTherapeutics, Inc. 97
Nanotherapeutics, Inc. 98
Alexza Pharmaceuticals, Inc. 99
Zogenix, Inc. 100
Neurocrine Biosciences, Inc. 101
Novartis AG 102
Aphios Corporation 103
EnVivo Pharmaceuticals 104
Acorda Therapeutics, Inc. 105
Astellas Pharma Inc. 106
EGIS Pharmaceuticals Plc 107
Elan Corporation, plc 108
Gedeon Richter Plc. 109
H Lundbeck A/S 110
Laboratoires Pierre Fabre SA 111
Les Laboratoires Servier 112
Mitsubishi Tanabe Pharma Corporation 113
Pain Therapeutics, Inc. 114
Pfizer Inc. 115
Teva Pharmaceutical Industries Limited 116
Zydus Cadila Healthcare Limited 117
Sun Pharmaceutical Industries Limited 118
Shire Plc 119
XTL Biopharmaceuticals Ltd. 120
NuPathe Inc. 121
Oxygen Biotherapeutics, Inc. 122
Collegium Pharmaceutical, Inc. 123
Addex Pharmaceuticals 124
Evotec Aktiengesellschaft 125
GW Pharmaceuticals plc 126
Proneuron Biotechnologies, Inc. 127
AEterna Zentaris Inc. 128
Neuralstem, Inc. 129
AVANIR Pharmaceuticals 130
Lpath, Inc. 131
Bionomics Limited 132
Neuren Pharmaceuticals Limited 133
NeuroSearch A/S 134
Catalyst Pharmaceutical Partners, Inc. 135
Corcept Therapeutics Incorporated 136
University of Florida 137
ACADIA Pharmaceuticals Inc. 138
Chelsea Therapeutics, Inc. 139
Mundipharma International Limited 140
Yuyu Pharma, Inc. 141
Hisamitsu Pharmaceutical Co., Inc. 142
Lund University 143
RegeneRx Biopharmaceuticals, Inc. 144
Titan Pharmaceuticals, Inc. 145
Dongwha Pharm Co., Ltd. 146
Biotie Therapies Corp. 147
Transition Therapeutics Inc. 148
Allon Therapeutics Inc. 149
Theravance, Inc. 150
Suven Life Sciences Ltd. 151
Orexo AB 152
Newron Pharmaceuticals S.p.A. 153
e-Therapeutics plc 154
Stem Cell Therapeutics Corp. 155
Rexahn Pharmaceuticals, Inc. 156
NeuroVive Pharmaceutical AB 157
Jiangsu Nhwa Pharma Corporation 158
Mithridion, Inc. 159
Intas Pharmaceuticals Ltd. 160
Mount Sinai School of Medicine 161
M et P Pharma AG 162
Spectrum Pharmaceuticals, Inc. 163
CoMentis, Inc. 164
Angelini Group 165
Humanetics Corporation 166
D-Pharm Ltd. 167
Camurus AB 168
Arbor Pharmaceuticals, Inc. 169
KeyNeurotek Pharmaceuticals AG 170
Snowdon Inc. 171
Domain Therapeutics 172
Helsinn Healthcare S.A. 173
Cristalia Produtos Quimicos Farmaceuticos Ltda. 174
Critical Pharmaceuticals Limited 175
Curemark, LLC 176
AGY Therapeutics, Inc. 177
Global Health Ventures Inc. 178
CoLucid Pharmaceuticals, Inc. 179
Supernus Pharmaceuticals, Inc. 180
Remedy Pharmaceuticals, Inc. 181
Fabre-Kramer Pharmaceuticals, Inc. 182
PsychoGenics, Inc. 183
Hydra Biosciences, Inc. 184
Adamas Pharmaceuticals, Inc. 185
NeuroNascent, Inc. 186
Azevan Pharmaceuticals, Inc. 187
vasopharm GmbH 188
CeNeRx BioPharma, Inc. 189
KangLaiTe USA 190
Dart NeuroScience LLC 191
Omeros Corporation 192
ImmunoVaccine Technologies Inc. 193
Intra-Cellular Therapies, Inc. 194
Peptron, Inc. 195
Targacept, Inc. 196
Ortho-McNeil Pharmaceuticals, Inc. 197
Cary Pharmaceuticals Inc. 198
CBio Limited 199
Vanda Pharmaceuticals Inc. 200
KYORIN Pharmaceutical Co., Ltd. 201
Galenea Corp. 202
Marinus Pharmaceuticals, Inc. 203
MAPREG 204
M's Science Corporation 205
Encore Therapeutics Inc. 206
BrainCells Inc. 207
Adamed Sp. z o.o. 208
Royalty Pharma 209
Neos Therapeutics, Inc. 210
KemPharm, Inc. 211
Selecta Biosciences, Inc. 212
Heptares Therapeutics Ltd. 213
Ascendis Pharma A/S 214
Envoy Therapeutics, Inc. 215
Embera NeuroTherapeutics, Inc. 216
Edison Pharmaceuticals, Inc. 217
Sinapis Pharma, Inc 218
Conformetrix Ltd 219
GENEXTRA S.p.A. 220
Lightlake Therapeutics Inc. 221
BHR Pharma, LLC. 222
TheraQuest Biosciences, LLC 223
Clera Inc. 224
Celtic Pharmaceutical Holdings L.P. 225
Beech Tree Labs, Inc. 226
Cognosci, Inc. 227
Reviva Pharmaceuticals Inc. 228
Promentis Pharmaceuticals, Inc. 229
Naurex, Inc. 230
STATegics, Inc. 231
PharmaNeuroBoost N.V. 232
Rhythm Pharmaceuticals 233
Psychiatric Disorders – Therapeutics Assessment 234
Assessment by Monotherapy Products 234
Assessment by Combination Products 235
Assessment by Route of Administration 236
Assessment by Molecule Type 239
Drug Profiles 242
zicronapine - Drug Profile 242
vortioxetine - Drug Profile 244
armodafinil - Drug Profile 246
lurasidone hydrochloride - Drug Profile 248
edivoxetine - Drug Profile 250
quetiapine fumarate ER - Drug Profile 252
brexpiprazole - Drug Profile 253
cariprazine hydrochloride - Drug Profile 255
levomilnacipran hydrochloride SR - Drug Profile 257
TGFK-07AD - Drug Profile 259
pimavanserin tartrate - Drug Profile 260
aripiprazole - Drug Profile 261
EVP-6124 - Drug Profile 264
amitifadine - Drug Profile 266
acetylcysteine - Drug Profile 268
NeuroSTAT - Drug Profile 270
biperiden - Drug Profile 271
aripiprazole - Drug Profile 272
anamorelin hydrochloride - Drug Profile 273
lisdexamfetamine dimesylate - Drug Profile 275
morphine sulfate - Drug Profile 276
epoetin alfa - Drug Profile 277
oxytocin - Drug Profile 278
Dehydroepiandrosterone + Hormone Replacement Therapy - Drug Profile 280
(pipamperone + citalopram) - Drug Profile 281
chlordiazepoxide + pioglitazone + [citalopram hydrobromide] - Drug Profile 283
lisdexamfetamine dimesylate - Drug Profile 284
progesterone - Drug Profile 287
allopurinol - Drug Profile 288
lithium carbonate - Drug Profile 289
aripiprazole lauroxil - Drug Profile 290
bitopertin - Drug Profile 291
diamorphine hydrochloride + [methadone] - Drug Profile 293
bexarotene - Drug Profile 294
cycloserine - Drug Profile 295
mifepristone - Drug Profile 296
tramadol hydrochloride - Drug Profile 297
YY-162 - Drug Profile 298
mifepristone - Drug Profile 299
methylphenidate hydrochloride - Drug Profile 300
sulfasalazine - Drug Profile 301
asenapine maleate - Drug Profile 302
methylphenidate - Drug Profile 303
nabilone - Drug Profile 304
agomelatine - Drug Profile 305
INASTR-001 - Drug Profile 306
immune globulin intravenous (human) - Drug Profile 307
blonanserin - Drug Profile 308
dexmesylamine hydrochloride + [SSRI] - Drug Profile 309
dexmesylamine hydrochloride + [SNRI] - Drug Profile 311
(naloxone hydrochloride + buprenorphine) - Drug Profile 313
baclofen ER - Drug Profile 314
trazodone hydrochloride - Drug Profile 315
blonanserin - Drug Profile 316
acetylcysteine - Drug Profile 318
ramelteon - Drug Profile 319
fluoxetine - Drug Profile 320
Projectx-1100 - Drug Profile 321
Psychiatric Disorders Therapeutics – Drug Profile Updates 322
Psychiatric Disorders Therapeutics – Discontinued Products 352
Psychiatric Disorders Therapeutics - Dormant Products 363
Psychiatric Disorders – Product Development Milestones 396
Featured News & Press Releases 396
Appendix 404
Methodology 404
Coverage 404
Secondary Research 404
Primary Research 404
Expert Panel Validation 404
Contact Us 405
Disclaimer 405
List of Tables
Number of Products Under Development for Psychiatric Disorders, H1 2013 21
Products under Development for Psychiatric Disorders – Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Development by Companies, H1 2013 (Contd..5) 29
Number of Products under Development by Companies, H1 2013 (Contd..6) 30
Number of Products under Development by Companies, H1 2013 (Contd..7) 31
Number of Products under Development by Companies, H1 2013 (Contd..8) 32
Number of Products under Development by Companies, H1 2013 (Contd..9) 33
Number of Products under Development by Companies, H1 2013 (Contd..10) 34
Number of Products under Development by Companies, H1 2013 (Contd..11) 35
Number of Products under Development by Companies, H1 2013 (Contd..12) 36
Number of Products under Development by Companies, H1 2013 (Contd..13) 37
Number of Products under Investigation by Universities/Institutes, H1 2013 39
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 40
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 41
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 42
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 43
Comparative Analysis by Late Stage Development, H1 2013 44
Comparative Analysis by Mid Clinical Stage Development, H1 2013 45
Comparative Analysis by Early Clinical Stage Development, H1 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 47
Products under Development by Companies, H1 2013 48
Products under Development by Companies, H1 2013 (Contd..1) 49
Products under Development by Companies, H1 2013 (Contd..2) 50
Products under Development by Companies, H1 2013 (Contd..3) 51
Products under Development by Companies, H1 2013 (Contd..4) 52
Products under Development by Companies, H1 2013 (Contd..5) 53
Products under Development by Companies, H1 2013 (Contd..6) 54
Products under Development by Companies, H1 2013 (Contd..7) 55
Products under Development by Companies, H1 2013 (Contd..8) 56
Products under Development by Companies, H1 2013 (Contd..9) 57
Products under Development by Companies, H1 2013 (Contd..10) 58
Products under Development by Companies, H1 2013 (Contd..11) 59
Products under Development by Companies, H1 2013 (Contd..12) 60
Products under Development by Companies, H1 2013 (Contd..13) 61
Products under Development by Companies, H1 2013 (Contd..14) 62
Products under Development by Companies, H1 2013 (Contd..15) 63
Products under Development by Companies, H1 2013 (Contd..16) 64
Products under Development by Companies, H1 2013 (Contd..17) 65
Products under Development by Companies, H1 2013 (Contd..18) 66
Products under Development by Companies, H1 2013 (Contd..19) 67
Products under Development by Companies, H1 2013 (Contd..20) 68
Products under Development by Companies, H1 2013 (Contd..21) 69
Products under Development by Companies, H1 2013 (Contd..22) 70
Products under Development by Companies, H1 2013 (Contd..23) 71
Products under Development by Companies, H1 2013 (Contd..24) 72
Products under Investigation by Universities/Institutes, H1 2013 73
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 74
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 75
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 76
Products under Investigation by Universities/Institutes, H1 2013 (Contd..4) 77
Products under Investigation by Universities/Institutes, H1 2013 (Contd..5) 78
Products under Investigation by Universities/Institutes, H1 2013 (Contd..6) 79
Bristol-Myers Squibb Company, H1 2013 80
DURECT Corporation, H1 2013 81
Johnson & Johnson, H1 2013 82
F. Hoffmann-La Roche Ltd., H1 2013 83
Aradigm Corporation, H1 2013 84
Amgen Inc., H1 2013 85
Sanofi-Aventis, H1 2013 86
AstraZeneca PLC, H1 2013 87
Eli Lilly and Company, H1 2013 88
BioDelivery Sciences International, Inc., H1 2013 89
Athersys, Inc., H1 2013 90
GlaxoSmithKline plc, H1 2013 91
Tekmira Pharmaceuticals Corp., H1 2013 92
Alkermes, Inc., H1 2013 93
Merck & Co., Inc., H1 2013 94
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 95
Taisho Pharmaceutical Co., Ltd., H1 2013 96
Euroscreen S.A., H1 2013 97
Otsuka Pharmaceutical Co., Ltd., H1 2013 98
Takeda Pharmaceutical Company Limited, H1 2013 99
Egalet a/s, H1 2013 100
CardioVascular BioTherapeutics, Inc., H1 2013 101
Nanotherapeutics, Inc., H1 2013 102
Alexza Pharmaceuticals, Inc., H1 2013 103
Zogenix, Inc., H1 2013 104
Neurocrine Biosciences, Inc., H1 2013 105
Novartis AG, H1 2013 106
Aphios Corporation, H1 2013 107
EnVivo Pharmaceuticals, H1 2013 108
Acorda Therapeutics, Inc., H1 2013 109
Astellas Pharma Inc., H1 2013 110
EGIS Pharmaceuticals Plc, H1 2013 111
Elan Corporation, plc, H1 2013 112
Gedeon Richter Plc., H1 2013 113
H Lundbeck A/S, H1 2013 114
Laboratoires Pierre Fabre SA, H1 2013 115
Les Laboratoires Servier, H1 2013 116
Mitsubishi Tanabe Pharma Corporation, H1 2013 117
Pain Therapeutics, Inc., H1 2013 118
Pfizer Inc., H1 2013 119
Teva Pharmaceutical Industries Limited, H1 2013 120
Zydus Cadila Healthcare Limited, H1 2013 121
Sun Pharmaceutical Industries Limited, H1 2013 122
Shire Plc, H1 2013 123
XTL Biopharmaceuticals Ltd., H1 2013 124
NuPathe Inc., H1 2013 125
Oxygen Biotherapeutics, Inc., H1 2013 126
Collegium Pharmaceutical, Inc., H1 2013 127
Addex Pharmaceuticals, H1 2013 128
Evotec Aktiengesellschaft, H1 2013 129
GW Pharmaceuticals plc, H1 2013 130
Proneuron Biotechnologies, Inc., H1 2013 131
AEterna Zentaris Inc., H1 2013 132
Neuralstem, Inc., H1 2013 133
AVANIR Pharmaceuticals, H1 2013 134
Lpath, Inc., H1 2013 135
Bionomics Limited, H1 2013 136
Neuren Pharmaceuticals Limited, H1 2013 137
NeuroSearch A/S, H1 2013 138
Catalyst Pharmaceutical Partners, Inc., H1 2013 139
Corcept Therapeutics Incorporated, H1 2013 140
University of Florida, H1 2013 141
ACADIA Pharmaceuticals Inc., H1 2013 142
Chelsea Therapeutics, Inc., H1 2013 143
Mundipharma International Limited, H1 2013 144
Yuyu Pharma, Inc., H1 2013 145
Hisamitsu Pharmaceutical Co., Inc., H1 2013 146
Lund University, H1 2013 147
RegeneRx Biopharmaceuticals, Inc., H1 2013 148
Titan Pharmaceuticals, Inc., H1 2013 149
Dongwha Pharm Co., Ltd., H1 2013 150
Biotie Therapies Corp., H1 2013 151
Transition Therapeutics Inc., H1 2013 152
Allon Therapeutics Inc., H1 2013 153
Theravance, Inc., H1 2013 154
Suven Life Sciences Ltd., H1 2013 155
Orexo AB, H1 2013 156
Newron Pharmaceuticals S.p.A., H1 2013 157
e-Therapeutics plc, H1 2013 158
Stem Cell Therapeutics Corp., H1 2013 159
Rexahn Pharmaceuticals, Inc., H1 2013 160
NeuroVive Pharmaceutical AB, H1 2013 161
Jiangsu Nhwa Pharma Corporation, H1 2013 162
Mithridion, Inc., H1 2013 163
Intas Pharmaceuticals Ltd., H1 2013 164
Mount Sinai School of Medicine, H1 2013 165
M et P Pharma AG, H1 2013 166
Spectrum Pharmaceuticals, Inc., H1 2013 167
CoMentis, Inc., H1 2013 168
Angelini Group, H1 2013 169
Humanetics Corporation, H1 2013 170
D-Pharm Ltd., H1 2013 171
Arbor Pharmaceuticals, Inc., H1 2013 173
KeyNeurotek Pharmaceuticals AG, H1 2013 174
Snowdon Inc., H1 2013 175
Domain Therapeutics, H1 2013 176
Helsinn Healthcare S.A., H1 2013 177
Cristalia Produtos Quimicos Farmaceuticos Ltda., H1 2013 178
Critical Pharmaceuticals Limited, H1 2013 179
Curemark, LLC, H1 2013 180
AGY Therapeutics, Inc., H1 2013 181
Global Health Ventures Inc., H1 2013 182
CoLucid Pharmaceuticals, Inc., H1 2013 183
Supernus Pharmaceuticals, Inc., H1 2013 184
Remedy Pharmaceuticals, Inc., H1 2013 185
Fabre-Kramer Pharmaceuticals, Inc., H1 2013 186
PsychoGenics, Inc., H1 2013 187
Hydra Biosciences, Inc., H1 2013 188
Adamas Pharmaceuticals, Inc., H1 2013 189
NeuroNascent, Inc., H1 2013 190
Azevan Pharmaceuticals, Inc., H1 2013 191
vasopharm GmbH, H1 2013 192
CeNeRx BioPharma, Inc., H1 2013 193
KangLaiTe USA, H1 2013 194
Dart NeuroScience LLC, H1 2013 195
Omeros Corporation, H1 2013 196
ImmunoVaccine Technologies Inc., H1 2013 197
Intra-Cellular Therapies, Inc., H1 2013 198
Peptron, Inc., H1 2013 199
Targacept, Inc., H1 2013 200
Cary Pharmaceuticals Inc., H1 2013 202
CBio Limited, H1 2013 203
Vanda Pharmaceuticals Inc., H1 2013 204
KYORIN Pharmaceutical Co., Ltd., H1 2013 205
Galenea Corp., H1 2013 206
Marinus Pharmaceuticals, Inc., H1 2013 207
MAPREG, H1 2013 208
M's Science Corporation, H1 2013 209
Encore Therapeutics Inc., H1 2013 210
BrainCells Inc., H1 2013 211
Adamed Sp. z o.o., H1 2013 212
Royalty Pharma, H1 2013 213
Neos Therapeutics, Inc., H1 2013 214
KemPharm, Inc., H1 2013 215
Selecta Biosciences, Inc., H1 2013 216
Heptares Therapeutics Ltd., H1 2013 217
Ascendis Pharma A/S, H1 2013 218
Envoy Therapeutics, Inc., H1 2013 219
Embera NeuroTherapeutics, Inc., H1 2013 220
Edison Pharmaceuticals, Inc., H1 2013 221
Sinapis Pharma, Inc, H1 2013 222
Conformetrix Ltd, H1 2013 223
GENEXTRA S.p.A., H1 2013 224
Lightlake Therapeutics Inc., H1 2013 225
BHR Pharma, LLC., H1 2013 226
TheraQuest Biosciences, LLC, H1 2013 227
Clera Inc., H1 2013 228
Celtic Pharmaceutical Holdings L.P., H1 2013 229
Beech Tree Labs, Inc., H1 2013 230
Cognosci, Inc., H1 2013 231
Reviva Pharmaceuticals Inc., H1 2013 232
Promentis Pharmaceuticals, Inc., H1 2013 233
Naurex, Inc., H1 2013 234
STATegics, Inc., H1 2013 235
PharmaNeuroBoost N.V., H1 2013 236
Rhythm Pharmaceuticals, H1 2013 237
Assessment by Monotherapy Products, H1 2013 238
Assessment by Combination Products, H1 2013 239
Assessment by Stage and Route of Administration, H1 2013 242
Assessment by Stage and Molecule Type, H1 2013 245
Psychiatric Disorders Therapeutics – Drug Profile Updates 326
Psychiatric Disorders Therapeutics – Discontinued Products 356
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..1) 357
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..2) 358
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..3) 359
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..4) 360
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..5) 361
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..6) 362
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..7) 363
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..8) 364
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..9) 365
Psychiatric Disorders Therapeutics – Discontinued Products (Contd..10) 366
Psychiatric Disorders Therapeutics – Dormant Products 367
Psychiatric Disorders Therapeutics – Dormant Products (Contd..1) 368
Psychiatric Disorders Therapeutics – Dormant Products (Contd..2) 369
Psychiatric Disorders Therapeutics – Dormant Products (Contd..3) 370
Psychiatric Disorders Therapeutics – Dormant Products (Contd..4) 371
Psychiatric Disorders Therapeutics – Dormant Products (Contd..5) 372
Psychiatric Disorders Therapeutics – Dormant Products (Contd..6) 373
Psychiatric Disorders Therapeutics – Dormant Products (Contd..7) 374
Psychiatric Disorders Therapeutics – Dormant Products (Contd..8) 375
Psychiatric Disorders Therapeutics – Dormant Products (Contd..9) 376
Psychiatric Disorders Therapeutics – Dormant Products (Contd..10) 377
Psychiatric Disorders Therapeutics – Dormant Products (Contd..11) 378
Psychiatric Disorders Therapeutics – Dormant Products (Contd..12) 379
Psychiatric Disorders Therapeutics – Dormant Products (Contd..13) 380
Psychiatric Disorders Therapeutics – Dormant Products (Contd..14) 381
Psychiatric Disorders Therapeutics – Dormant Products (Contd..15) 382
Psychiatric Disorders Therapeutics – Dormant Products (Contd..16) 383
Psychiatric Disorders Therapeutics – Dormant Products (Contd..17) 384
Psychiatric Disorders Therapeutics – Dormant Products (Contd..18) 385
Psychiatric Disorders Therapeutics – Dormant Products (Contd..19) 386
Psychiatric Disorders Therapeutics – Dormant Products (Contd..20) 387
Psychiatric Disorders Therapeutics – Dormant Products (Contd..21) 388
Psychiatric Disorders Therapeutics – Dormant Products (Contd..22) 389
Psychiatric Disorders Therapeutics – Dormant Products (Contd..23) 390
Psychiatric Disorders Therapeutics – Dormant Products (Contd..24) 391
Psychiatric Disorders Therapeutics – Dormant Products (Contd..25) 392
Psychiatric Disorders Therapeutics – Dormant Products (Contd..26) 393
Psychiatric Disorders Therapeutics – Dormant Products (Contd..27) 394
Psychiatric Disorders Therapeutics – Dormant Products (Contd..28) 395
Psychiatric Disorders Therapeutics – Dormant Products (Contd..29) 396
Psychiatric Disorders Therapeutics – Dormant Products (Contd..30) 397
Psychiatric Disorders Therapeutics – Dormant Products (Contd..31) 398
Psychiatric Disorders Therapeutics – Dormant Products (Contd..32) 39
List of Figures
Number of Products under Development for Psychiatric Disorders, H1 2013 21
Products under Development for Psychiatric Disorders – Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 38
Late Stage Products, H1 2013 44
Mid Clinical Stage Products, H1 2013 45
Early Clinical Stage Products, H1 2013 46
Discovery and Pre-Clinical Stage Products, H1 2013 47
Assessment by Monotherapy Products, H1 2013 238
Assessment by Combination Products, H1 2013 239
Assessment by Route of Administration, H1 2013 240
Assessment by Stage and Route of Administration, H1 2013 241
Assessment by Molecule Type, H1 2013 243
Assessment by Stage and Molecule Type, H1 2013 244
To order this report:
Therapy Industry: Psychiatric Disorders – Pipeline Review, H1 2013
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article